Neal Ready
0000-0003-4414-9432
Publication & Citation Trends
Publications
0 total
Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study
Cited by 0
Semantic Scholar
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis OA
Cited by 4
Semantic Scholar
Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial OA
Cited by 13
Semantic Scholar
Tumor-Associated Molecules Lead the Way to New Therapies for Small Cell Lung Cancer.
Cited by 0
Semantic Scholar
Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer.
Cited by 0
Semantic Scholar
LRP1B loss predicts sensitivity to immunotherapy in patients with NSCLC: an analysis of the phase 3 Checkmate 026 randomized trial.
Cited by 1
Semantic Scholar
TIGOS-LS, an open-label, randomized study of BMS-986489 vs durvalumab as consolidation therapy following chemoradiotherapy in limited-stage small-cell lung cancer.
Cited by 0
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(122)
Cancer Immunotherapy and Biomarkers
(118)
Lung Cancer Research Studies
(92)
Lung Cancer Diagnosis and Treatment
(49)
Immunotherapy and Immune Responses
(40)
Affiliations
Hershey (United States)
University of Maryland, Baltimore
University of Minnesota
Memorial Sloan Kettering Cancer Center
Roger Williams Medical Center